ChemoCentryx, Inc. (CCXI): Price and Financial Metrics

ChemoCentryx, Inc. (CCXI): $51.68

0.04 (+0.08%)

POWR Rating

Component Grades













Add CCXI to Watchlist
Sign Up

Industry: Biotech



in industry


  • Growth is the dimension where CCXI ranks best; there it ranks ahead of 60.63% of US stocks.
  • CCXI's strongest trending metric is Quality; it's been moving up over the last 177 days.
  • CCXI ranks lowest in Stability; there it ranks in the 2nd percentile.

CCXI Stock Summary

  • CCXI's price/sales ratio is 98.8; that's higher than the P/S ratio of 97.83% of US stocks.
  • As for revenue growth, note that CCXI's revenue has grown 72.52% over the past 12 months; that beats the revenue growth of 87.16% of US companies in our set.
  • In terms of volatility of its share price, CCXI is more volatile than 88.85% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to CHEMOCENTRYX INC are QUIK, VIVE, PROF, CERS, and BFLY.
  • Visit CCXI's SEC page to see the company's official filings. To visit the company's web site, go to

CCXI Valuation Summary

  • In comparison to the median Healthcare stock, CCXI's price/sales ratio is 5100% higher, now standing at 98.8.
  • Over the past 129 months, CCXI's price/sales ratio has gone up 87.7.

Below are key valuation metrics over time for CCXI.

Stock Date P/S P/B P/E EV/EBIT
CCXI 2022-09-23 98.8 15.6 -27.7 -28.4
CCXI 2022-09-22 99.1 15.6 -27.8 -28.5
CCXI 2022-09-21 99.1 15.6 -27.8 -28.5
CCXI 2022-09-20 99.1 15.6 -27.8 -28.5
CCXI 2022-09-19 98.7 15.6 -27.6 -28.4
CCXI 2022-09-16 98.7 15.6 -27.6 -28.4

CCXI Growth Metrics

    Its year over year net cashflow from operations growth rate is now at 39.91%.
  • Its 5 year net income to common stockholders growth rate is now at -48.68%.
  • Its 2 year revenue growth rate is now at -19.16%.
Over the past 70 months, CCXI's revenue has gone up $30,234,000.

The table below shows CCXI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 37.28 -53.498 -133.094
2022-03-31 27.33 -45.223 -140.652
2021-12-31 32.224 -75.621 -131.755
2021-09-30 34.267 -83.958 -121.103
2021-06-30 21.609 -74.797 -122.856
2021-03-31 69.236 -75.264 -63.38

CCXI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CCXI has a Quality Grade of D, ranking ahead of 9.23% of graded US stocks.
  • CCXI's asset turnover comes in at 0.043 -- ranking 329th of 682 Pharmaceutical Products stocks.
  • LUMO, CBAY, and BPTH are the stocks whose asset turnover ratios are most correlated with CCXI.

The table below shows CCXI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.043 1 -0.262
2021-03-31 0.132 1 -0.148
2020-12-31 0.145 1 -0.163
2020-09-30 0.191 1 -0.166
2020-06-30 0.262 1 -0.190
2020-03-31 0.159 1 -0.476

CCXI Price Target

For more insight on analysts targets of CCXI, see our CCXI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $32.50 Average Broker Recommendation 1.31 (Strong Buy)

CCXI Stock Price Chart Interactive Chart >

Price chart for CCXI

CCXI Price/Volume Stats

Current price $51.68 52-week high $51.85
Prev. close $51.64 52-week low $14.95
Day low $51.64 Volume 1,325,500
Day high $51.76 Avg. volume 1,735,789
50-day MA $45.08 Dividend yield N/A
200-day MA $30.74 Market Cap 3.69B

ChemoCentryx, Inc. (CCXI) Company Bio

ChemoCentryx, Inc. focuses on the discovery, development, and commercialization of orally administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. The company was founded in 1997 and is based in Mountain View, California.

CCXI Latest News Stream

Event/Time News Detail
Loading, please wait...

CCXI Latest Social Stream

Loading social stream, please wait...

View Full CCXI Social Stream

Latest CCXI News From Around the Web

Below are the latest news stories about CHEMOCENTRYX INC that investors may wish to consider to help them evaluate CCXI as an investment opportunity.

Why Is Ionis Pharmaceuticals (IONS) Down 5.8% Since Last Earnings Report?

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | September 8, 2022

Why Is ChemoCentryx (CCXI) Up 1.4% Since Last Earnings Report?

ChemoCentryx (CCXI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | September 7, 2022

7 Dow Stocks With Superior Fundamentals

While investors look for safe bets, here are seven Dow stocks to buy in September.

Tezcan Gecgil on InvestorPlace | September 6, 2022

How Covid, 'industrial logic' and a threat played out in a multibillion-dollar biotech merger

Ultimately, Amgen agreed to pay a price $8 per share larger than its nearest competitor for a 25-year-old company with one FDA-approved drug.

Yahoo | September 1, 2022

These 10 Non-Covid Biotech Stocks Are Up 40% Or More This Year

Biotech stocks are scorching right now. But the best of the best have strong gains. Those include 10 with at least 40% growth this year.

Yahoo | August 29, 2022

Read More 'CCXI' Stories Here

CCXI Price Returns

1-mo 1.29%
3-mo 93.12%
6-mo 93.20%
1-year 164.21%
3-year 662.24%
5-year 596.50%
YTD 41.94%
2021 -41.20%
2020 56.56%
2019 262.51%
2018 83.36%
2017 -19.59%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.458 seconds.